On November 04, 2015 OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) reported that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific alone and in combination with anti-Programmed Cell Death Protein 1 (PD1) will be presented at the upcoming Society of Immunotherapy for Cancer (SITC) (Free SITC Whitepaper) 30th Annual Meeting taking place November 4-8, 2015 in National Harbor, MD (Press release, OncoMed, NOV 4, 2015, View Source [SID:1234507950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Saturday, November 7, 2015 – 12:45 pm — 2:00 pm

Title: Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses

Lead author: Angie Park, PhD, Director of Immunotherapy and Stem Cell Biology, of OncoMed

Session: Optimizing Combination Immunotherapy